Org. Process Res. Dev. 2022, 26, 5, 1398–1404
Categories
Tags
Analytical Chemistry
Analytical Science
Artificial Intelligence (AI)
Biocatalysis
Catalysis
CatSci Paper
CatSci Patent
Chemical Development
Complex Synthetic Medicines
Design of Experiments
Digital
Drug Development
Experimental Design
Green Chemistry
Industry insights
Innovation
Machine Learning (ML)
Material Science
Medium Throughput Experimentation
Oligonucleotides
Peptides
Principal Component Analysis
Process R&D
PROTACs
QbD
Route Scouting and Selection
Scale-up
Scavenging
Solvents
Sustainability
Technology transfer
Work-up
Org. Process Res. Dev. 2022, 26, 5, 1458–1469
CatSci's Senior Scientist, Dr Alice Dunbabin, participated in the latest Chemistry Today panel discussion on Catalysis.
Access the recordings of our 10-year anniversary symposium now. The event was centred on the future of medicines development and featured industry-leading speakers from AstraZeneca, Bristol Myers Squibb, DeepMatter, FogPharma, Merck, Novartis, R.I, Roche, Syngenta, and more.
Our CCO, Dr Simon Tyler, argues that to achieve true sustainability, a more holistic approach to overall drug development is needed.
Access the recordings of our second virtual symposium now. The event featured an impressive itinerary of three eminent speakers from industry, who delivered digestible 30-minute presentations, covering topics from high throughput experimentation in organic synthesis to separation technology and analytical science.
Speed and efficiency are everything in pharmaceutical synthesis – and that’s why biocatalysis is an increasingly attractive option.
Development of a flow scavenging protocol
Dr Alan Steven explains why environmental sustainability and “big picture thinking” should be key considerations when selecting solvents for scale-up.
CatSci was tasked with designing a new bromination method for a key reaction intermediate. Use of bromine rendered the previous process unsuitable for a larger campaign and would require expensive and time-consuming alterations to the plant.
The route supplied by the client involved the use of phenyl cyanate for functionalising a heterocyclic intermediate with a nitrile group. Its ongoing use would require cyanide monitoring, a dedicated waste stream treatment step, and there were concerns over the sourcing of material of appropriate quality over the long term.
The client's Phase 1 process was struggling to deliver API in low kg qualities. In particular, Intermediate B was of variable quality, and residual metals were known to negatively affect the onward chemistry.
CatSci was tasked with performing route-scouting, route selection and early-phase process development over a 6-month period to meet a pilot plant manufacturing slot.
CatSci was tasked with the development of a regioselective Buchwald-Hartwig amination for the final bond forming step of an API. The inherited conditions were not robust with respect to reaction conversion leading to stability concerns.
CatSci's Senior Principal Scientist, Dr Alan Steven presented a free webinar organised by Scientific Update, entitled ‘Faster, Cleaner and Greener: Why chemistry in micellar and micellar-like media is now a viable option for chemical development and beyond’.
Our CEO, Dr Ross Burn talks about surviving and thriving as a new company focused on process chemistry, alongside more recent moves into industry 4.0 and collaborations in the contract research space.
Access the recordings of our first virtual symposium now. The event featured an impressive itinerary of four eminent speakers spanning industry and academia, who delivered digestible 30-minute presentations, covering topics from green technologies to material science, such as crystallisation.
WO2020023438
Chem. Eur. J., 2020, 26, 1–12
Org. Process Res. Dev. 2020, 24, 6, 897–908
Dalton Trans., 2020, 49, 8169-8178